SCHEMBL8317609

SCHEMBL8317609

CC(Nc1ncnc2cc(C(=O)N3CCCC(CCN)C3)c(Cl)cc12)c1nc2cc(Cl)ccc2[nH]1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 2/20 0.37
TLR7 Q9NYK1 2/20 0.37
TLR9 Q9NR96 1/20 0.37
KMT2A Q03164 1/20 0.35
PDE2A O00408 3/20 0.35
AKR1C3 P42330 1/20 0.34
EGFR P00533 3/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
FGFR1 P11362 1/20 0.34
FLT1 P17948 1/20 0.34
FLT4 P35916 1/20 0.34
KDR P35968 1/20 0.34
BTK Q06187 3/20 0.34
TSHR P16473 1/20 0.34
GRM5 P41594 1/20 0.34
GSK3B P49841 1/20 0.33
CNR1 P21554 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4149366 0.94 TLR9 (0.36) TLR8TLR7TLR9KMT2APDE2A
SCHEMBL4149373 0.94 TLR9 (0.36) TLR8TLR7TLR9KMT2APDE2A
SCHEMBL8321511 0.94 TLR9 (0.36) TLR8TLR7TLR9KMT2APDE2A
SCHEMBL8322561 0.91 SYK (0.39) KMT2APDE2AEGFRNPC1RAB9A
SCHEMBL4165662 0.91 PDE2A (0.35) KMT2APDE2AEGFRFGFR1FLT1
SCHEMBL4153812 0.91 SYK (0.39) KMT2APDE2AEGFRNPC1RAB9A
SCHEMBL4153811 0.91 SYK (0.39) KMT2APDE2AEGFRNPC1RAB9A
SCHEMBL4150711 0.90 CNR1 (0.36) TLR8TLR7TLR9EGFRBTK
SCHEMBL4141398 0.90 CNR1 (0.36) TLR8TLR7TLR9EGFRBTK
SCHEMBL4882052 0.90 CNR1 (0.36) TLR8TLR7TLR9EGFRBTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181958-A1 SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-07-16 US disclosed
US-20090181958-A1 SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-07-16 US disclosed
US-7429597-B2 Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) 2008-09-30 US disclosed
US-7429597-B2 Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) 2008-09-30 US disclosed
WO-2004058743-A1 NOVEL SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES AND USE THEREOF AS FACTOR XA INHIBITORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181958-A1 SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS F12, F11, F2 TLR8 4701/4885TLR7 3447/4885TLR9 3710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.